Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug class may change how the bladder behaves

NCT ID NCT07716774

Knowledge-focused Sponsor: Marmara University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study looks at how SGLT-2 inhibitors, a common class of diabetes drugs, affect lower urinary tract symptoms such as frequent urination, urgency, and nighttime trips to the bathroom. Researchers will follow adults with type 2 diabetes who are starting an SGLT-2 inhibitor for the first time, tracking their bladder symptoms using a diary and a questionnaire before and after one month of treatment. The goal is to better understand any changes in bladder function that may occur with this medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGLT-2 inhibitor (a class of diabetes drugs that lower blood sugar by causing the kidneys to excrete glucose in urine)
What this could lead to
If this study finds a link, it could help doctors better understand how SGLT-2 inhibitors affect bladder function and guide treatment choices for people with diabetes.
What could go wrong
This is a small, observational study without a control group, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults (≥18 years) with type 2 diabetes mellitus who are newly prescribed oral SGLT-2 inhibitor therapy during routine clinical practice. Eligible patients without pre-existing conditions or treatments that could significantly affect lower urinary tract symptoms will be prospectively followed for one month. Lower urinary tract symptoms will be assessed using a 3-day bladder diary and the OAB-v8 questionnaire at baseline and at the one-month follow-up.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years of age) * Patients with type 2 diabetes mellitus newly initiated on oral SGLT-2 inhibitor therapy Exclusion Criteria: * Age \<18 years * Patients with insulin-dependent diabetes mellitus (IDDM) * Patients with diabetes-related complications (e.g., diabetic nephropathy, retinopathy, or vasculopathy) * Patients receiving anticholinergic or α-blocker therapy for lower urinary tract symptoms (LUTS) * History of urinary incontinence surgery (including any surgical procedure involving the urethral sphincter, bladder neck, pelvic floor, or pelvic nerves) * Patients with urinary tract infection (UTI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lower urinary track symptoms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

overactive bladder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lower urinary track symptoms Overactive bladder SGLT2 inhibitors

Contacts and locations

Locations

  • Marmara University School of Medicine Urology Department

    Istanbul, Pendik, 34854, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.